Evotec AG has earned a $ 2 million milestone payment from Second Genome, Inc., a microbiome discovery and development company, for the initiation of a Phase II clinical study of SGM-1019, a first-in-class oral therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). The Phase II trial of SGM-1019 has been initiated following the completion of two successful Phase I trials. The companies have been collaborating since 2015 for the discovery and development of novel microbiome asset...